| Jenna Henry, | |
|
417 Village Dr., Suite 4, Carlisle, PA 17015 | |
| (717) 245-0610 | |
| Not Available |
| Full Name | Jenna Henry |
|---|---|
| Gender | Female |
| Speciality | Qualified Speech Language Pathologist |
| Experience | 6 Years |
| Location | 417 Village Dr., Carlisle, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306470802 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SL014993 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Phs Physical Therapy Llc | 9234454851 | 98 |
News Archive
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Musculoskeletal injuries comprise a large percentage of hospital admissions for adults and often lead to chronic pain and long-term disability.
Chronic pain results from disease or trauma to the nervous system. Damaged nerve fibres with heightened responses to normal stimuli send incorrect messages to pain centres in the brain. This phenomenon, called "peripheral and central sensitization" is one of the key mechanisms involved in the condition which touches people with diabetes, cancer, and those suffering from multiple sclerosis, among others.
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
› Verified 5 days ago
| Provider Name | Phs Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1912300096 PECOS PAC ID: 9234454851 Enrollment ID: O20150202001629 |
News Archive
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Musculoskeletal injuries comprise a large percentage of hospital admissions for adults and often lead to chronic pain and long-term disability.
Chronic pain results from disease or trauma to the nervous system. Damaged nerve fibres with heightened responses to normal stimuli send incorrect messages to pain centres in the brain. This phenomenon, called "peripheral and central sensitization" is one of the key mechanisms involved in the condition which touches people with diabetes, cancer, and those suffering from multiple sclerosis, among others.
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jenna Henry, 1849 Holly Dr, Camp Hill, PA 17011-7421 Ph: () - | Jenna Henry, 417 Village Dr., Suite 4, Carlisle, PA 17015 Ph: (717) 245-0610 |
News Archive
Amylin Pharmaceuticals, Inc. today announced that it has submitted the initial sections of a rolling submission for a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the use of metreleptin to treat diabetes and/or hypertriglyceridemia (high levels of triglycerides in the bloodstream) in patients with rare forms of lipodystrophy.
Musculoskeletal injuries comprise a large percentage of hospital admissions for adults and often lead to chronic pain and long-term disability.
Chronic pain results from disease or trauma to the nervous system. Damaged nerve fibres with heightened responses to normal stimuli send incorrect messages to pain centres in the brain. This phenomenon, called "peripheral and central sensitization" is one of the key mechanisms involved in the condition which touches people with diabetes, cancer, and those suffering from multiple sclerosis, among others.
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.
› Verified 5 days ago
Nichole Jennifer Reynolds, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3 Jennifer Ct, Suite A, Carlisle, PA 17015 Phone: 717-243-0271 Fax: 717-243-0531 | |
Gail Yvonne Kemeny, M.S. CCC/SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 940 Walnut Bottom Rd, Carlisle, PA 17015 Phone: 717-249-0085 Fax: 717-249-0647 | |
Abbie Rose Lookingbill, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Longsdorf Way, Carlisle, PA 17015 Phone: 717-309-1889 | |
Hannah Yohn, Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 417 Village Dr Ste 4, Carlisle, PA 17015 Phone: 717-245-0610 | |
Heidi Ann Stearns, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1 Longsdorf Way, Carlisle, PA 17015 Phone: 717-462-4028 | |
Stephanie Mcgarrell, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 271 Hoy Rd, Carlisle, PA 17013 Phone: 717-258-8431 | |
Summer Dacheux, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 804 Belvedere St, Carlisle, PA 17013 Phone: 717-512-2841 |